Supraventricular Tachycardia (SVT)

Comprehensive Clinical Guide: Supraventricular Tachycardia (SVT)

Supraventricular Tachycardia (SVT) represents a heterogeneous group of tachyarrhythmias originating above the Bundle of His. While often benign in healthy individuals, SVT can precipitate significant hemodynamic instability in patients with underlying structural heart disease. This guide serves as a definitive clinical resource for medical professionals and clinical specialists.

1. Clinical Definition and Overview

SVT is defined as a tachycardia with a rate typically exceeding 100 beats per minute (bpm) at rest, originating from the atria or the atrioventricular (AV) junction. Unlike ventricular tachycardias (VT), which arise below the Bundle of His, SVT mechanisms are primarily driven by re-entry circuits or enhanced automaticity involving the sinoatrial node, atrial tissue, or the AV node.

Epidemiological Snapshot

• Prevalence: Approximately 2.25 per 1,000 in the general population.
• Demographics: Higher incidence in females and patients over age 65.
• Clinical Significance: Accounts for a substantial percentage of emergency department visits for palpitations and syncope.

2. Pathophysiology and Mechanisms

The pathophysiology of SVT is rooted in the electrophysiological properties of the cardiac conduction system. The primary mechanisms include:

A. Re-entry (The Most Common Mechanism)

Re-entry requires two pathways with different conduction velocities and refractory periods, joined at both ends to form a closed loop.
* AV Nodal Re-entrant Tachycardia (AVNRT): The most frequent form, involving dual pathways within the AV node (slow and fast pathways).
* AV Reciprocating Tachycardia (AVRT): Involves an accessory pathway (e.g., Wolff-Parkinson-White syndrome) that bypasses the AV node, creating a macro-re-entrant circuit.

B. Enhanced Automaticity

This occurs when ectopic foci (atrial or junctional) fire at a rate faster than the sinus node. This is often triggered by electrolyte disturbances, hypoxia, or catecholamine excess.

C. Triggered Activity

Delayed after-depolarizations (DADs) or early after-depolarizations (EADs) can trigger repetitive firing, commonly seen in digitalis toxicity.

3. Clinical Staging and Classification

Clinicians categorize SVT based on the ECG morphology and the involvement of the AV node.

4. Standard Presentation and Differential Diagnosis

Clinical Presentation

Patients typically present with:
* Palpitations: Often described as a rapid, regular "fluttering" in the chest.
* Dizziness/Lightheadedness: Resulting from transient hypotension.
* Dyspnea: Due to decreased cardiac output and pulmonary venous congestion.
* Chest Pain: Especially in patients with underlying coronary artery disease (CAD).
* Syncope: A "red flag" symptom indicating severe hemodynamic compromise.

Differential Diagnosis

It is critical to distinguish SVT from:
1. Ventricular Tachycardia (VT): Crucial differentiation as VT can be life-threatening.
2. Sinus Tachycardia: Usually a physiological response to stress, fever, or exercise.
3. Atrial Fibrillation: Characterized by irregularly irregular rhythm.

5. Diagnostic Evaluation

A systematic diagnostic approach is required to confirm SVT and rule out structural pathologies.

Key Diagnostic Tests

• 12-Lead ECG: The gold standard. Look for narrow QRS complexes (<120ms) and specific P-wave morphology.
• Holter/Event Monitoring: Indicated for patients with intermittent, non-sustained episodes.
• Echocardiogram: Essential to evaluate for structural heart disease (e.g., valvular issues, cardiomyopathy).
• Electrophysiology Study (EPS): Invasive mapping used for definitive diagnosis and pre-ablation planning.

6. Management and Clinical Indications

Acute Management

1. Vagal Maneuvers: Valsalva maneuver, carotid sinus massage (with caution).
2. Pharmacological Therapy:
   • Adenosine: First-line agent (6mg rapid IV bolus).
   • Calcium Channel Blockers (Diltiazem/Verapamil): For rate control in patients without hypotension.
   • Beta-blockers: For sympathetic-mediated tachycardias.
3. Synchronized Cardioversion: Indicated for patients with hemodynamic instability (hypotension, altered mental status, signs of shock).

Long-Term Management

• Catheter Ablation: The curative treatment of choice for recurrent AVNRT and AVRT. Success rates exceed 95%.
• Pharmacological Prophylaxis: Used if the patient declines ablation or is not a candidate. Includes beta-blockers, Flecainide, or Sotalol.

7. Risks, Contraindications, and Prognosis

Contraindications

• Adenosine: Contraindicated in patients with asthma (may trigger bronchospasm) or 2nd/3rd-degree heart block.
• Verapamil/Diltiazem: Contraindicated in patients with heart failure with reduced ejection fraction (HFrEF) or known WPW with atrial fibrillation (risk of accelerated conduction).

Prognosis

• General: Excellent for most patients, particularly those undergoing successful catheter ablation.
• Risk Factors for Recurrence: Older age, presence of structural heart disease, and duration of the tachycardia.

8. Frequently Asked Questions (FAQ)

1. Is SVT life-threatening?

In the vast majority of cases, SVT is not life-threatening. However, it can cause severe symptoms. If the heart rate remains elevated for a prolonged period, it can lead to tachycardia-induced cardiomyopathy.

2. Can caffeine cause SVT?

Caffeine is a known trigger for palpitations and can lower the threshold for SVT in susceptible individuals, though it rarely causes the tachycardia itself in a healthy heart.

3. What is the difference between SVT and AFib?

SVT is typically a regular, narrow-complex rhythm originating above the ventricles. Atrial fibrillation is an irregularly irregular rhythm caused by chaotic electrical activity in the atria.

4. How does the Valsalva maneuver work?

It increases intrathoracic pressure, stimulating the vagus nerve, which increases parasympathetic tone to the AV node, effectively "resetting" the electrical circuit.

5. Is catheter ablation dangerous?

Catheter ablation is a minimally invasive procedure with a low risk of complications (e.g., <1% risk of AV block requiring a pacemaker).

6. Can I exercise with SVT?

Generally, yes, once the SVT is well-controlled. However, symptomatic episodes during exercise warrant a full cardiology workup.

7. What is "Wide-Complex SVT"?

This occurs when an SVT is accompanied by bundle branch block or aberrant conduction. It is notoriously difficult to differentiate from Ventricular Tachycardia; therefore, it should be treated as VT until proven otherwise.

8. Does pregnancy affect SVT?

Pregnancy can increase the frequency of SVT episodes due to hormonal changes and increased blood volume. Management requires careful selection of antiarrhythmic drugs that are safe for the fetus.

9. What is the role of the "Slow Pathway" in AVNRT?

The slow pathway is the target for ablation. By destroying this pathway, the re-entry circuit is permanently broken, preventing the tachycardia.

10. When should I go to the Emergency Department?

Seek immediate care if you experience chest pain, fainting, shortness of breath, or if your heart rate remains high despite rest and vagal maneuvers.

9. Clinical Summary Table: Therapeutic Decision Making

Conclusion

Supraventricular Tachycardia is a dynamic and manageable condition when approached with a rigorous clinical framework. By utilizing the diagnostic hierarchy—from surface ECG to invasive electrophysiology—clinicians can offer patients definitive cures through catheter ablation, effectively restoring quality of life and preventing long-term cardiac remodeling. Always maintain a high index of suspicion for underlying structural heart disease and prioritize the exclusion of ventricular tachyarrhythmias in all wide-complex clinical presentations.